학술논문
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Document Type
Erratum
Author
Zhou, Caicun; Wang, Ziping; Sun, Meili; Cao, Lejie; Ma, Zhiyong; Wu, Rong; Yu, Yan; Yao, Wenxiu; Sun, Si; Chen, Jianhua; Zhuang, Wu; Cui, Jiuwei; Chen, Xueqin; Lu, You; Shen, Hong; Hu, Chunhong; Liu, Jiwei; Liu, Yunpeng; Wang, Mengzhao; Li, Xingya; Sun, Ping; Shu, Yongqian; Zhou, Jianying; Li, Jingzhang; Gu, Kangsheng; Wang, Changli; Zhao, Hui; Zhang, Yiping; Liu, Chunling; Wang, Jingru; Chen, Rumei; Qin, Mengmeng; Wang, Hao; Yang, Jason
Source
Nature Cancer. 5(1):209-209
Subject
Language
English
ISSN
2662-1347